Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Retained Earnings (2016 - 2025)

Dare Bioscience's Retained Earnings history spans 11 years, with the latest figure at -$421623.0 for Q4 2025.

  • For Q4 2025, Retained Earnings rose 1.68% year-over-year to -$421623.0; the TTM value through Dec 2025 reached -$421623.0, up 1.68%, while the annual FY2025 figure was -$421623.0, 1.68% up from the prior year.
  • Retained Earnings reached -$421623.0 in Q4 2025 per DARE's latest filing, up from -$187.2 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$98229.0 in Q1 2021 to a low of -$187.2 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$66.7 million, with a median of -$479774.5 recorded in 2022.
  • Peak YoY movement for Retained Earnings: soared 99.81% in 2021, then crashed 120536.47% in 2022.
  • A 5-year view of Retained Earnings shows it stood at -$154973.0 in 2021, then plummeted by 90931.75% to -$141.1 million in 2022, then soared by 99.74% to -$360896.0 in 2023, then fell by 18.82% to -$428809.0 in 2024, then increased by 1.68% to -$421623.0 in 2025.
  • Per Business Quant, the three most recent readings for DARE's Retained Earnings are -$421623.0 (Q4 2025), -$187.2 million (Q3 2025), and -$402826.0 (Q2 2025).